Open AccessDo We Still Need Lead‐in Dosing of Nevirapine in HIV‐Infected Patients Who Are Receiving Rifampicin‐Containing Antituberculous Therapy?
Author(s) -
SuiYuan Chang,
ShuWen Lin,
ChienChing Hung
Publication year - 2009
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/644494
Subject(s) - medicine , nevirapine , dosing , rifampicin , lead (geology) , human immunodeficiency virus (hiv) , virology , intensive care medicine , tuberculosis , antiretroviral therapy , viral load , pathology , geomorphology , geology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom